Selecting the embryos with the best implantation potential for IFV

par | Jan 15, 2019

Increase the success of in vitro fertilization by selecting the embryos with the best implantation potential

SATT Sud-Est transfers to DiaSys Technologies a biomarker that increases the chances of success of in vitro fertilization, thanks to the support of the Eurobiomed cluster

SATT Sud-Est announces an exclusive license on a co-ownership patent of Aix-Marseille Université, Inserm, Assistance Publique – Hôpitaux de Marseille, Centre Hospitalier Universitaire de Nîmes and Université de Montpellier, to DiaSys Technologies, an Occitan subsidiary of the DiaSys Diagnostics Systems Group (Germany), a leading developer and manufacturer of high quality diagnostic solutions. The license is for CD146 protein, an embryo selection biomarker with the best implantation potential for in vitro fertilization (IVF). The action of the health competitiveness cluster of the south of France Eurobiomed was decisive in bringing together its member, DiaSys Technologies, and SATT Sud-Est. It is the historic partnership between Eurobiomed and SATT Sud-Est that has made it possible to bring together the private and public research sectors.Despite significant advances in reproductive biology, determining the number of embryos to be implanted in IVF remains a difficult step. To date, embryos are selected by microscopy according to imperfect morphological criteria, leading to multiple pregnancies or even pregnancy failures. Resulting from research at the Reproductive Biology Laboratory of the Conception Hospital in Marseille (AP-HM), the Cardiovascular and Nutrition Research Centre (C2VN UMR-S 1263), the laboratory “Dysfunction of Vascular Interfaces – Feminine Characteristics of Cardiovascular Interfaces” (EA nb 2992), and the Hematology Laboratory of the University Hospital of Nîmes, the technology offers a new non-invasive tool to accurately determine the embryos with the best chances of success in IVF based on the expression level of CD146 protein in the embryo culture medium.SATT Sud-Est has filed and manages a patent that protects the technology. Co-maturation and sub-licensing agreements have been signed between SATT Sud-Est and DiaSys Technologies. Objectives: to validate the results on an extended cohort and adapt the biomarker assay to DiaSys Technologies’ proprietary technology. DiaSys Technologies will develop and propose a new kit for the analysis of the chances of success of embryo implantation for medically assisted reproduction services. Read more, download press release.

For further information

Twitter

@SATTse_ @univamu @Insermpacacorse @aphm_actu @CHUNimes @umontpellier @PoleEurobiomed

Passer de l’invention à l’innovation est un émerveillement. Et nous avons de la chance, c’est notre métier.

Découvrez comment la SATT Sud-Est accélère le transfert de technologies en fédérant les acteurs de la recherche et de l’entreprise. Du brevet à la licence d’exploitation, en passant par la preuve de concept, la SATT Sud-Est s’impose dans les Régions Sud et Corse comme un acteur incontournable de l’innovation.

Siège
Le Silo, 35 Quai du Lazaret, CS 70545
13304 Marseille Cedex 02

La SATT Sud-Est
Projet financé avec le concours de l'Union Européenne avec le Fonds Européen de Développement Régional.